The Bengaluru-based Centre for Cellular and Molecular Platform (C-CAMP), and One Nucleus, the Cambridge(UK) based life science and healthcare membership organisation, have signed a strategic partnership agreement to promote and encourage collaborations between life science researchers and companies/members in both regions/ countries.

Through this collaboration, the two organisations aim to foster scientific and business collaborations by facilitating networking and partnering meetings as well as hosting visiting delegations from each other’s countries.

C-CAMP and One Nucleus will act as a gateway for information sharing and facilitation and enable start-ups and research institutes to leverage the innovation ecosystem in each other’s leading clusters.

Explaining the partnership, Dr Taslimarif Saiyed, Director and COO, C-CAMP said, “In the last couple of years, C-CAMP has worked extensively to establish a robust life science innovation and entrepreneurship ecosystem in and around Bengaluru, which nurtures many start-ups all over India with support from DBT and BIRAC. This partnership with One Nucleus provides an opportunity for C-CAMP to make stronger ties with the Cambridge/London cluster — one of the leading innovation ecosystems in the world. We are hopeful of some ground-breaking collaborations and outcomes from this partnership in the coming years.”

Harriet Fear, CEO of One Nucleus added, “Many of our members are interested in exploring opportunities with the Indian market but they either have limited knowledge or experience of the potential for collaboration and mutual advancement. I am hugely excited to have entered into this strategic relationship with C-CAMP. My team and I look forward to building the blocks for, and with, our members and the Indian community.”

The agreement was initiated during the February 2015 UK drug development mission to Bangalore BIO run by UK Trade and Investment, and finalised during a meeting with Harriet Fear, CEO, One Nucleus and UK Business Ambassador, during that trip.

comment COMMENT NOW